Rallybio Corporation
RLYB
$0.66
$0.011.17%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 0.00% | 0.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 0.00% | 0.00% | |||
| Cost of Revenue | -19.09% | -89.21% | |||
| Gross Profit | 29.06% | 92.64% | |||
| SG&A Expenses | -28.63% | 0.91% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -30.50% | 3.92% | |||
| Operating Income | 31.14% | -4.00% | |||
| Income Before Tax | 265.06% | -2.80% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 265.06% | -2.80% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 265.06% | -2.80% | |||
| EBIT | 31.14% | -4.00% | |||
| EBITDA | 31.31% | -4.03% | |||
| EPS Basic | 264.23% | -2.66% | |||
| Normalized Basic EPS | 33.73% | -2.58% | |||
| EPS Diluted | 264.23% | -2.66% | |||
| Normalized Diluted EPS | 33.73% | -2.58% | |||
| Average Basic Shares Outstanding | 0.49% | 0.15% | |||
| Average Diluted Shares Outstanding | 0.49% | 0.15% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||